HLA Class II Alleles are associated with Anti-Drug Antibodies in Ulcerative Colitis Patients Treated with Etrolizumab
Saha, A.; McCarthy, M. I.; Fischer, S. K.; Sperinde, G.; Hammer, C.
Show abstract
Patients treated with etrolizumab, a monoclonal antibody drug for ulcerative colitis, often develop anti-drug antibodies (ADA) and neutralizing antibodies (NAb). To investigate genetic risk factors, we evaluated associations between HLA alleles and ADA/NAb development. HLA-DQB1*06:03 demonstrated the most significant association with both ADA (OR = 7.3, P [≤] 7.6x10-13) and NAb (OR = 13.1, P [≤] 7.7x10-13). After controlling for HLA-DQB1*06:03, HLA-DQA1*03:03 emerged as the next most significant allele associated with ADA (OR = 2.8, P [≤] 1.0x10-3) and NAb (OR = 5.0, P [≤] 1.3x10-3). Notably, all patients carrying both alleles (n=5) developed ADA, suggesting these two alleles are sufficient to induce ADA to etrolizumab.
Matching journals
The top 17 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Association of Naïve B Cells with Humoral Response to SARS-CoV-2 Vaccination 92%
- Development and Validation of Multivariable Prediction Models of Serological Response to SARS-CoV-2 Vaccination in Kidney Transplant Recipients 91%
- Characterization of the impact of daclizumab beta on circulating natural killer cells by mass cytometry 91%
Similar papers in this journal
Similar papers in this journal
- IL-1 and IL-6 inhibitor hypersensitivity link to common HLA-DRB1*15 alleles 93%
- Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial 92%
- BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in Systemic Lupus Erythematosus 92%
Similar papers in this journal
- Integrative Mendelian Randomization approaches for therapeutic target prioritisation in immune-mediated diseases 91%
- Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study 90%
- Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.